Latest Conference Coverage

Details Behind the Phase 3 MyClad Study of Cladribine in Myasthenia Gravis

Study investigator Henry Kaminski, MD, provided clinical insight on a unique trial assessing the efficacy and safety of oral cladribine tablets, an FDA-approved medication for multiple sclerosis, in patients with myasthenia gravis.

Subcutaneous Efgartigimod PH20 Efficacious in Patients With CIDP Previously Treated

A recent analysis of the phase 3 ADHERE trial demonstrated the clinical benefit of subcutaneous efgartigimod PH20 in patients with chronic inflammatory demyelinating polyneuropathy.

Clinical Insights From Phase 3 VIVACITY-MG3 Study of Nipocalimab in Generalized Myasthenia Gravis

Tuan Vu, MD, a professor of neurology at the University of South Florida, provided brief commentary on topline data of the phase 3 VIVACITY-MG3 study presented at AANEM 2024.

Phase 3 Trial to Assess Therapeutic Effect of IV Efgartigimod in Seronegative Myasthenia Gravis

The phase 3 study is expected to include 110 patients with seronegative myasthenia gravis who will be randomly assigned to IV efgartigimod or placebo for a 5-week follow-up, followed by an open-label extension.

RAISE-XT Interim Analysis Shows Sustained Efficacy of Long-Term Zilucoplan Treatment in Generalized Myasthenia Gravis

Therapeutic Potential of Self-Administered Subcutaneous Rozanolixizumab in Myasthenia Gravis: Rachana K. Gandhi Mehta, MBBS

The assistant professor of neurology at Wake Forest School of Medicine provided clinical insight on MG0020, a phase 3 trial assessing a self-administration of rozanolixizumab through a syringe driver. [WATCH TIME: 3 minu]

Ranging Cycle Cadence of Rozanolixizumab Highlights Need for Individualized Treatment Approach

Despite balanced baseline characteristics, patients ranged from low to high number of rozanolixizumab treatment cycles, suggesting the need for a personalized approach.

Episode 126: Exploring the Therapeutic Potential of ATH434 in Multiple System Atrophy

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Claassen, MD, MS. [LISTEN TIME: 14 minutes]

Phase 3b ADAPT NXT Study Confirms Efficacy of Cyclic and Biweekly Dosing of Efgartigimod in Generalized Myasthenia Gravis

Findings showed that both fixed cycles and every-other-week dosing regimens of efgartigimod were well tolerated and effective in improving clinical outcomes in patients with generalized myasthenia gravis.

Phase 3 PREVAIL Study to Test Bispecific Nanoantibody Gefurulimab in Generalized Myasthenia Gravis

The PREVAIL trial, presented at the 2024 AANEM meeting, is investigating gefurulimab, a bispecific nanoantibody designed to inhibit complement activation, as a potential treatment for patients with generalized myasthenia gravis.

Therapeutic Benefits of Steroid-Sparing Effect From New Myasthenia Gravis Medications: Christopher Scheiner, MD, PhD

The neuromuscular specialist at the University of Tennessee Medical Center provided clinical insight on a retrospective analysis studying the long-term corticosteroid patterns of approved treatments for generalized myasthenia gravis. [WATCH TIME: 5 minutes]

Rozanolixizumab Efficacious in Older Patients With Generalized Myasthenia Gravis, Phase 3 Data Show

Rozanolixizumab demonstrated efficacy in patients with generalized myasthenia gravis aged at least 65 years, despite a higher incidence of comorbidities observed in this population.

Innovative MyClad Study Testing Cladribine Capsules in Generalized Myasthenia Gravis: Henry Kaminski, MD

The Meta A. Neumann Professor of Neurology at George Washington University provided an overview of a new phase 3 study testing the efficacy and safety of cladribine versus placebo in generalized myasthenia gravis. [WATCH TIME: 3 minutes]

Phase 3 NIMBLE Trial to Test Effects of Pozelimab and Cemdisiran in Myasthenia Gravis

Pozelimab and cemdisiran work together to block the complement pathway, which plays a key role in gMG, using two different approaches—one suppresses liver production of a key protein, while the other targets it directly with antibodies.

Complement Inhibition of Zilucoplan Unaffected When Used Concomitantly With IVIg, Plasma Exchange

Zilucoplan, approved for generalized myasthenia gravis in 2023, showed consistent complement inhibition, even with additional treatments like IVIg or plasma exchange.

Understanding the Therapeutic Potential of Inebilizumab in Myasthenia Gravis: Richard Nowak, MD, MS

The director of the myasthenia gravis clinic at Yale University provided clinical insight on promising phase 3 data assessing inebilizumab, an FDA-approved therapy for NMOSD, in patients with myasthenia gravis. [WATCH TIME: 4 minutes]

Cipaglucosidase Alfa/Miglustat Therapy Improves Efficacy Outcomes in Enzyme Replacement Therapy-Experienced Patients With Late-Onset Pompe Disease

A new analysis of the phase 3 PROPEL study showed that switching to cipaglucosidase alfa/miglustat therapy enhanced outcomes among patients with late-onset Pompe disease.

Meta-Analysis Reveals Significant Burden of Cardiovascular Comorbidities in Myasthenia Gravis

Using data from observational studies, a recent meta-analysis offered a comprehensive overview of the risk profile of cardiovascular comorbidities in patients with myasthenia gravis.

Daily Oral Edaravone Fails to Display Superiority in Phase 3B Study MT-1186-A02 for ALS

A new study presented at AANEM 2024 revealed that daily dosing of oral edaravone was well tolerated and did not reveal any new safety concerns in patients with amyotrophic lateral sclerosis.

Concomitant Corticosteroid Use Decreased in Myasthenia Gravis Through Ravulizumab

Long-term use of ravulizumab in patients with generalized myasthenia gravis led to a significant reduction in corticosteroid dependence, highlighting its potential steroid-sparing benefits.

Understanding the Therapeutic Potential of GT-02287 in GBA-Parkinson Disease

Jonas Hannestad, MD, PhD, chief medical officer at Gain Therapeutics, provided clinical perspective on promising data from a phase 1 first-in-human study of GT-02287, an investigational therapy for Parkinson disease with or without a GBA1 mutation.

Vutrisiran Treatment Leads to Quality of Life Enhancements in hATTR-Polyneuropathy

Over an 18-month period, patients showed strengthened scores on Rasch-built Overall Disability Scale, a patient-reported outcome measure of activity and social participation.

HNSA-5487 Significantly Reduces IgG Levels, FDA Removes Hold on AOC 1001, DMD Gene Therapy Shows No Impact on Cardiac Outcomes

Duchenne Gene Therapy Shows No Alteration of Cardiac Outcomes in Phase 3 EMBARK Study

After 52 weeks of treatment, no significant differences were found in cardiac MRI measures such as ejection fraction, end diastolic volume, or circumferential strain between the two groups.

Mechanism of Stem Cell Therapy Bemdaneprocel for Parkinson Disease: Amit Rakhit, MD

The chief medical officer and chief development officer at BlueRock Therapeutics discussed the promise behind bemdaneprocel and its unique mechanism of action relative to other Parkinson disease treatments. [WATCH TIME: 3 minutes]

Exploring the Impact of Circadian Rhythms on Glial Function and Alzheimer Disease

Erik Musiek, MD, PhD, a professor of neurology at Washington University in St. Louis, provided clinical insight on a presentation from ANA 2024 highlighting the intricate relationship between circadian rhythms, glial activation, and neuroinflammation in Alzheimer disease.

NeuroVoices: Joseph Kuchling, MD, on Bridging Gaps in Autoimmune Condition Overlap With New MS Diagnostic Criteria

The postdoctoral research assistant at Charité University Berlin discussed how the new diagnostic criteria for multiple sclerosis could offer earlier detection, especially in those with overlapping autoimmune conditions, through advanced imaging markers.

Distinct Alzheimer Disease Subtypes Using Proteomic Fingerprints: Fiona Elwood, PhD

The disease area stronghold leader in neurodegeneration at Johnson & Johnson discussed data presented at AAIC 2024 highlighting different subtypes of Alzheimer disease that may lead to more personalized treatments. [WATCH TIME: 4 minutes]

Clinical Utility of Middle Meningeal Artery Embolization as an Adjunctive Treatment of Subdural Hematoma

Michelle Bravo, MD, an assistant professor of clinical neurology at the University of Miami, provided commentary on a rare case report of a subdural hematoma linked to spontaneous intracranial hypotension caused by a refractory CSF leak.

Advancing Multiple Sclerosis Diagnosis With the 2024 Criteria Revision: Xavier Montalban, MD, PhD

The chair of neurology at Hospital Universitari Vall d’Hebron talked about the revision of the MS diagnostic criteria that will integrate new evidence, biological markers, and advanced MRI findings to enable earlier and more precise diagnoses. [WATCH TIME: 4 minutes]